The efficacy and safety of adalimumab in ocular inflammatory disease
Authors Arcinue CA, Durrani K, Artornsombudh P, Radwan A, Parikh R, Suelves A, Siddique S, Chang I, Preble J, Foster CS
Received 24 February 2015
Accepted for publication 29 June 2015
Published 31 August 2015 Volume 2015:5 Pages 69—74
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Lise Aagaard
Cheryl A Arcinue,1,2 Khayyam Durrani,1–3 Pichaporn Artornsombudh,1,2 Alaa Radwan,1,2 Ravi Parikh,1,2 Ana M Suelves,1,2 Sana S Siddique,1,2 Ian Chang,1,2 Janine M Preble,1,2 Charles Stephen Foster1–3
1Massachusetts Eye Research and Surgery Institution, 2Ocular Immunology and Uveitis Foundation, Cambridge, 3Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
Objective: To evaluate the efficacy and safety of adalimumab in the management of ocular inflammation at our institution.
Methods: We performed a review of all patients with active ocular inflammation treated with adalimumab at our institution.
Results: Seventy eyes of 49 patients were reviewed. The mean duration of follow-up was 19.6 months. Therapy with an average of 2.1 immunomodulatory agents had been attempted prior to adalimumab therapy. At 1-year follow-up, adalimumab was effective in achieving quiescence in 33 eyes (47%). The most common side effects were injection-site reactions, arthralgias, and nausea, occurring in two patients each. Adalimumab was discontinued due to side effects in 12 patients.
Conclusion: These results suggest that adalimumab is an effective and safe therapeutic modality in ocular inflammation.
Keywords: uveitis, biologic response modifier, TNF-α, adverse effects, therapeutic outcomes, scleritis, peripheral ulcerative keratitis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]